Company Analysis
Sign in

AEON Biopharma, Inc. (AEON)

NYSE: AEON · Pharmaceutical Preparations · Irvine, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade4.4
◀ Past 5.7● Present 2.0▶ Future 5.7
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$39.2M-193.4%
Earnings per share$-3.95-105.4%
Operating cash flow-$17.3M+14.7%
Cash$3.0M+23023.1%
Debtn/a
Shareholders’ equity-$55.0M-92.6%
Shares, diluted9,921,587+1622.7%
Return on equityn/a
The recordfrom its filings
Filings in 202656
Newest filingNov 10 · SCHEDULE 13D/A
Annual reportMar 30, 2026
Quarterly reportAug 12, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted1
Filer category<br>Emerging growth company
Trailing twelve months to Jun 2026Net income -$54.6MCash from operations -$13.6Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
21222425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Oct 26, 2026 · SEC EDGAR · Form DEF 14A
Proxy statement
Open the filing on sec.gov
Oct 23, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Sep 30, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
Aug 21, 2026 · SEC EDGAR · Form SCHEDULE 13G
Large holder notice
Open the filing on sec.gov
Aug 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton AEON · research, not advice